I Gulturk, C Kapar, E Arslan, M Polat, G B Sonmezoz, D Tural
{"title":"按照RECIP 1.0标准评价去势敏感前列腺癌的治疗效果。","authors":"I Gulturk, C Kapar, E Arslan, M Polat, G B Sonmezoz, D Tural","doi":"10.1016/j.acuroe.2025.501837","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the relationship between treatment response and radiological progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) assessed by PSMA-PET/CT using Response Evaluation Criteria on PSMA (RECIP 1.0) criteria.</p><p><strong>Methods: </strong>In this study, 116 patients were analyzed retrospectively. At the beginning of the treatment and week 12 were PSMA PET/CT images evaluated for changes in total tumor volüme and new lesions. Patients were divided into four groups according to RECIP criteria; complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). The primary outcome was the correlation of RECIP criteria with rPFS.</p><p><strong>Results: </strong>Mean age of the patients was 67 years [IQR: 62-72]. Total of 116 patients; 65 (56%) hadPR, 17 (14,6%) SD, 19 (16,3%) PD, and 15 (12%) CR. rPFS was found to be statistically significantly different among these four groups (p < 0.001). RECIP PD was found to be significantly shorter rPFS compared with non-PD (p < 0.001), with an rPFS of 7 months (95% CI: 3.45-10.56). PSA values were measured at nadir in 40 patients and no patient in this group was evaluated as having PD.</p><p><strong>Conclusion: </strong>RECIP criteria have been shown to have prognostic significance in terms of evaluating treatment response and rPFS in mCSPC patients.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501837"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of treatment efficacy according to RECIP 1.0 criteria in castration-sensitive prostate cancer.\",\"authors\":\"I Gulturk, C Kapar, E Arslan, M Polat, G B Sonmezoz, D Tural\",\"doi\":\"10.1016/j.acuroe.2025.501837\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the relationship between treatment response and radiological progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) assessed by PSMA-PET/CT using Response Evaluation Criteria on PSMA (RECIP 1.0) criteria.</p><p><strong>Methods: </strong>In this study, 116 patients were analyzed retrospectively. At the beginning of the treatment and week 12 were PSMA PET/CT images evaluated for changes in total tumor volüme and new lesions. Patients were divided into four groups according to RECIP criteria; complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). The primary outcome was the correlation of RECIP criteria with rPFS.</p><p><strong>Results: </strong>Mean age of the patients was 67 years [IQR: 62-72]. Total of 116 patients; 65 (56%) hadPR, 17 (14,6%) SD, 19 (16,3%) PD, and 15 (12%) CR. rPFS was found to be statistically significantly different among these four groups (p < 0.001). RECIP PD was found to be significantly shorter rPFS compared with non-PD (p < 0.001), with an rPFS of 7 months (95% CI: 3.45-10.56). PSA values were measured at nadir in 40 patients and no patient in this group was evaluated as having PD.</p><p><strong>Conclusion: </strong>RECIP criteria have been shown to have prognostic significance in terms of evaluating treatment response and rPFS in mCSPC patients.</p>\",\"PeriodicalId\":94291,\"journal\":{\"name\":\"Actas urologicas espanolas\",\"volume\":\" \",\"pages\":\"501837\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Actas urologicas espanolas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.acuroe.2025.501837\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.acuroe.2025.501837","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的：应用PSMA反应评价标准（RECIP 1.0）评价PSMA- pet /CT评估转移性去雄敏感前列腺癌（mCSPC）患者治疗反应与放射学无进展生存期（rPFS）的关系。方法：对116例患者进行回顾性分析。在治疗开始和第12周时，评估PSMA PET/CT图像，以评估总肿瘤体积和新病变的变化。根据RECIP标准将患者分为4组；完全缓解（CR）、部分缓解（PR）、病情稳定（SD）和病情进展（PD）。主要结局是RECIP标准与rPFS的相关性。结果：患者平均年龄67岁[IQR: 62-72]。116例患者；hadPR 65例（56%），SD 17例（14.6%），PD 19例（16.3%），cr 15例（12%）。四组患者的rPFS差异有统计学意义(p结论：RECIP标准在评估mCSPC患者的治疗反应和rPFS方面具有预后意义。
Evaluation of treatment efficacy according to RECIP 1.0 criteria in castration-sensitive prostate cancer.
Objective: To evaluate the relationship between treatment response and radiological progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) assessed by PSMA-PET/CT using Response Evaluation Criteria on PSMA (RECIP 1.0) criteria.
Methods: In this study, 116 patients were analyzed retrospectively. At the beginning of the treatment and week 12 were PSMA PET/CT images evaluated for changes in total tumor volüme and new lesions. Patients were divided into four groups according to RECIP criteria; complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). The primary outcome was the correlation of RECIP criteria with rPFS.
Results: Mean age of the patients was 67 years [IQR: 62-72]. Total of 116 patients; 65 (56%) hadPR, 17 (14,6%) SD, 19 (16,3%) PD, and 15 (12%) CR. rPFS was found to be statistically significantly different among these four groups (p < 0.001). RECIP PD was found to be significantly shorter rPFS compared with non-PD (p < 0.001), with an rPFS of 7 months (95% CI: 3.45-10.56). PSA values were measured at nadir in 40 patients and no patient in this group was evaluated as having PD.
Conclusion: RECIP criteria have been shown to have prognostic significance in terms of evaluating treatment response and rPFS in mCSPC patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
